Several combinations of differentially methylated gene promoter regions were found to be more effective than single gene promoters (RASSF1A/RARB2, SHOX2/PTGER4, RTEL1/PCDHGB6, HOXD10/PAX9/PTPRN2/STAG3, APC/AIM1/CDH1/DCC/MGMT/RASSF1A) in distinguishing lung cancer patients from noncancerous controls [109]. The gene discussed is SHOX2; the disease is lung carcinoma.